母细胞性浆细胞样树突状细胞肿瘤的研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v6i1.6672
Abstract
母细胞性浆细胞样树突状细胞肿瘤(BPDCN)是一种起源于浆细胞样树突状细胞(pDC)前体、非常罕见的高度侵袭性的血液系统恶性肿瘤,长期生存率低,预后极差。由于其在临床上很少见,对该病认识不足极易造成漏诊、误诊,使患者错过最佳治疗时机。故本文主要从BPDCN的实验室诊断及鉴别诊断等方面进行综述,旨在提高临床及实验室人员对此病的认识和诊断水平。
Keywords
母细胞性浆细胞样树突状细胞肿瘤；细胞形态；免疫表型
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Shi Y, Wang E. Blastic plasmacytoid dendritic cell neoplasm:a clinicopathologic review[J].Arch Pathol Lab Med, 2014,138(4):564-569.
[2] Arber DA,Orazi A,Hasserjian R,et al. The 2016 revision to theWorld Health Organization classification of myeloid neo plasms andacute leukemia.Blood,2016,127(20):2391-2405.
[3] WHO Classification of Tumours Editorial Board. Haem atolymphoid tumours. Lyon (France): International Agency for Research on Cancer;2022.
[4] Venugopal S, Zhou S, El Jamal SM, et al. Blastic plasm acytoiddendritic cell neoplasm-current insights[J].Clin Lymp homaMyeloma Leuk,2019,19(9):545-554.
[5] 程平,王秋香,王兰兰.母细胞性浆细胞样树突细胞肿瘤患者的临床分析[J].中国实验血液学杂志,2023,31(3):896-901.
[6] Pagano L, Valentini CG, Grammatico S, et al. Blastic plasmacytoiddendritic cell neoplasm: diagnostic criteria and therapeuticalapproaches[J].Br J Haematol, 2016,174(2):188-202.
[7] 张茂功,董欣,杨朋.母细胞性浆细胞样树突细胞肿瘤[J].临床皮肤科杂志,2022,51(02):67+65-66.
[8] 方颖慧,王卫国,张华.母细胞性浆细胞样树突状细胞肿瘤临床与实验室特点分析[J].检验医学,2022,37(05):433-437.
[9] 吴灵珍,于倩,蒋谊.母细胞性浆细胞样树突细胞肿瘤患者的临床特点[J].中国实验血液学杂志,2020,28(1):307-313.
[10] Zhang Y, Sokol L. Clinical Insights into the Managem ent of Blastic Plasmacytoid Dendritic Cell Neoplasm[J].Cancer Manag Res,2022,14:2107-2117.
[11] 曹春育,陈丽华,戴桂红.母细胞性浆细胞样树突细胞肿瘤2例临床病理研究[J].安徽医药,2023,27(9):1861-1864+1911.
[12] JEGALIAN A G, BUXBAUM N P, FACCHETTI F, etal. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications[J].Haematologica,2010,95 (11):1873-1879.
[13] Ascani S,Massone C,Ferrara G,et al.CD4-negative varia nt of CD4+/CD56+ hematodermic neoplasm: description of thre e cases.[J].Journal of Cutaneous Pathology,2010,35(10):911-915.
[14] Leroux D,Mugneret F,Callanan M ,et al.CD4(+),CD56(+)DC2 acute leukemia is characterized by recurrent clonal chrom osomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique.[J]. Blood,2002,99(11):4154-4159.
[15] Sullivan JM, Rizzieri DA. Treatment of blastic plasm acytoiddendritic cell neoplasm[J].Hematology Am Soc Hematol EducProgram,2016,2016(1):16-23.
[16] Rai MP, Bedi PS, Kandola SK , et al. Blastic plasmacyt oiddendritic cell neoplasm[J].Clin Case Rep,2018,6(4):770-772.
[17] SAPIENZA M R, PILERI A, DERENZINI E, et al.Blastic plasmacytoid dendritic cell neoplasm: state of theart and prospects[J].Cancers(Basel),2019,11(5).
[18] TESTA U, PELOSI E, CASTELLI G. CD123 as a therapeutic target in the treatment of hematological Malignancies[J].Ca ncers (Basel),2019,11(9):1358.
[19] BEIRD H C, KHAN M, WANG F, et al. Features ofnonactivation dendritic state and immune deficiency inblastic plasmacytoid dendritic cell neoplasm ( BPDCN)[J].Blood Cancer J,2019,9(12):99.
[20] Cuglievan B,Connors J, He J,et al. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents,and young adults(AYA) and an update of novel therapies[J].Leukemia,2023,37(9):1767-1778.
[2] Arber DA,Orazi A,Hasserjian R,et al. The 2016 revision to theWorld Health Organization classification of myeloid neo plasms andacute leukemia.Blood,2016,127(20):2391-2405.
[3] WHO Classification of Tumours Editorial Board. Haem atolymphoid tumours. Lyon (France): International Agency for Research on Cancer;2022.
[4] Venugopal S, Zhou S, El Jamal SM, et al. Blastic plasm acytoiddendritic cell neoplasm-current insights[J].Clin Lymp homaMyeloma Leuk,2019,19(9):545-554.
[5] 程平,王秋香,王兰兰.母细胞性浆细胞样树突细胞肿瘤患者的临床分析[J].中国实验血液学杂志,2023,31(3):896-901.
[6] Pagano L, Valentini CG, Grammatico S, et al. Blastic plasmacytoiddendritic cell neoplasm: diagnostic criteria and therapeuticalapproaches[J].Br J Haematol, 2016,174(2):188-202.
[7] 张茂功,董欣,杨朋.母细胞性浆细胞样树突细胞肿瘤[J].临床皮肤科杂志,2022,51(02):67+65-66.
[8] 方颖慧,王卫国,张华.母细胞性浆细胞样树突状细胞肿瘤临床与实验室特点分析[J].检验医学,2022,37(05):433-437.
[9] 吴灵珍,于倩,蒋谊.母细胞性浆细胞样树突细胞肿瘤患者的临床特点[J].中国实验血液学杂志,2020,28(1):307-313.
[10] Zhang Y, Sokol L. Clinical Insights into the Managem ent of Blastic Plasmacytoid Dendritic Cell Neoplasm[J].Cancer Manag Res,2022,14:2107-2117.
[11] 曹春育,陈丽华,戴桂红.母细胞性浆细胞样树突细胞肿瘤2例临床病理研究[J].安徽医药,2023,27(9):1861-1864+1911.
[12] JEGALIAN A G, BUXBAUM N P, FACCHETTI F, etal. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications[J].Haematologica,2010,95 (11):1873-1879.
[13] Ascani S,Massone C,Ferrara G,et al.CD4-negative varia nt of CD4+/CD56+ hematodermic neoplasm: description of thre e cases.[J].Journal of Cutaneous Pathology,2010,35(10):911-915.
[14] Leroux D,Mugneret F,Callanan M ,et al.CD4(+),CD56(+)DC2 acute leukemia is characterized by recurrent clonal chrom osomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique.[J]. Blood,2002,99(11):4154-4159.
[15] Sullivan JM, Rizzieri DA. Treatment of blastic plasm acytoiddendritic cell neoplasm[J].Hematology Am Soc Hematol EducProgram,2016,2016(1):16-23.
[16] Rai MP, Bedi PS, Kandola SK , et al. Blastic plasmacyt oiddendritic cell neoplasm[J].Clin Case Rep,2018,6(4):770-772.
[17] SAPIENZA M R, PILERI A, DERENZINI E, et al.Blastic plasmacytoid dendritic cell neoplasm: state of theart and prospects[J].Cancers(Basel),2019,11(5).
[18] TESTA U, PELOSI E, CASTELLI G. CD123 as a therapeutic target in the treatment of hematological Malignancies[J].Ca ncers (Basel),2019,11(9):1358.
[19] BEIRD H C, KHAN M, WANG F, et al. Features ofnonactivation dendritic state and immune deficiency inblastic plasmacytoid dendritic cell neoplasm ( BPDCN)[J].Blood Cancer J,2019,9(12):99.
[20] Cuglievan B,Connors J, He J,et al. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents,and young adults(AYA) and an update of novel therapies[J].Leukemia,2023,37(9):1767-1778.
Copyright © 2024 孙雪梅, 张萍
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License